Search

Mannitol busulfan

Mm has been used in trials studying the treatment of Cocaine Dependence and Diabetes Mellitus, Type 2.

Nipocalimab

[L64042] It is an aglycosylated, fully human IgG1 monoclonal antibody that binds FcRn and blocks the receptor's recycling of immunoglobulin G (IgG), thereby lowering circulating IgG levels, including pathogenic … [L64043,L64045] On August 24, 2026, the FDA approved it for warm autoimmune hemolytic anemia (wAIHA), making it the first therapy approved for that condition.[L64043,L64044,L64045]

Grazoprevir

When combined together, Grazoprevir and [DB11574] as the combination product Zepatier have been shown to achieve a SVR between 94% and 97% for genotype 1 and 97% and 100% for genotype 4 after 12 weeks … Grazoprevir and [DB11574] are used with or without [DB00811] with the intent to cure, or achieve a sustained virologic response (SVR), after 12 weeks of daily therapy.

Flurpiridaz F-18

[A264519] Flurpiridaz F-18 is an analog of pyridaben, a mitochondrial complex 1 (MC-1) inhibitor.[L51659] … Flurpiridaz F-18 is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI), which is an imaging process used in patients with known or suspected

Dinutuximab

It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk … neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

Merbromin

It is an organomercuric disodium salt compound and a fluorescein that is available in many countries, except Switzerland, France, Germany, and the United States where the drug was withdrawn from market

Ferrous gluconate

Tivozanib

It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524] … Renal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74.

Sarilumab

cascades of IL-6. … [A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid

Lusutrombopag

x 10^9/L were administered lusutrombopag orally [L4166]. … Higher percentages (65-78%) of the patients receiving lusutrombopag required no platelet transfusion prior to the primary invasive procedure compared to those receiving placebo [L4166].